stockrowAddex Therapeutics Ltd. Sponsored ADR
ADXN Healthcare Biotechnology
Addex Therapeutics Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $36,200.00, down 92.1% from fiscal 2024.
- Revenue
- −86.0%
- EPS
- +25.8%
- Free cash flow
- −2.73%
Quarter to June 2026, against a year earlier
Follow ADXN
Alert me
Addex Therapeutics Ltd. Sponsored ADR (ADXN) EV/Sales
As of 6 November 2026, Addex Therapeutics Ltd. Sponsored ADR (ADXN) trades at a EV/Sales of 8.7×. Over the past ten years it has ranged from −4.9× (December 2022) to 48.3× (October 2023); the current reading is higher than 73% of that period. That is in line with the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 21.5× | 410.50% |
| FY2024 | 4.2× | — |
| FY2023 | −0.2× | — |
| FY2022 | −1.5× | — |
| FY2021 | 4.2× | (59.31%) |
| FY2020 | 10.3× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 21.5× | (19.98%) |
| Sep 2025 | 26.8× | 537.97% |
| Dec 2024 | 4.2× | (34.96%) |
| Sep 2024 | 6.5× | 174.40% |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PBLA Panbela Therapeutics Inc. compare | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | 0.7× |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | 1.5× |
| KALA KALA BIO, Inc. compare | 8.0× |
| ADXN Addex Therapeutics Ltd. Sponsored ADR | 8.7× |
| ONCO Onconetix, Inc. compare | 14.6× |
| ERNA Ernexa Therapeutics Inc. compare | 50.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)